DK0875252T3 - Formuleringer af aktiveret protein C - Google Patents

Formuleringer af aktiveret protein C

Info

Publication number
DK0875252T3
DK0875252T3 DK98303311T DK98303311T DK0875252T3 DK 0875252 T3 DK0875252 T3 DK 0875252T3 DK 98303311 T DK98303311 T DK 98303311T DK 98303311 T DK98303311 T DK 98303311T DK 0875252 T3 DK0875252 T3 DK 0875252T3
Authority
DK
Denmark
Prior art keywords
formulations
activated protein
protein
activated
Prior art date
Application number
DK98303311T
Other languages
English (en)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0875252T3 publication Critical patent/DK0875252T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98303311T 1997-04-28 1998-04-28 Formuleringer af aktiveret protein C DK0875252T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
DK0875252T3 true DK0875252T3 (da) 2005-04-25

Family

ID=21936854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98303311T DK0875252T3 (da) 1997-04-28 1998-04-28 Formuleringer af aktiveret protein C

Country Status (35)

Country Link
US (4) US6162629A (da)
EP (2) EP0875563A3 (da)
JP (2) JP4383546B2 (da)
KR (2) KR100450856B1 (da)
CN (2) CN1227025C (da)
AR (2) AR012010A1 (da)
AT (1) ATE285788T1 (da)
AU (2) AU743531B2 (da)
BR (2) BR9809292A (da)
CA (2) CA2287267C (da)
CO (2) CO4940438A1 (da)
CZ (1) CZ298429B6 (da)
DE (1) DE69828330T2 (da)
DK (1) DK0875252T3 (da)
EA (2) EA002149B1 (da)
EG (1) EG23685A (da)
ES (1) ES2234072T3 (da)
HK (1) HK1016472A1 (da)
HU (2) HUP0003401A3 (da)
ID (2) ID22933A (da)
IL (2) IL132502A0 (da)
IN (2) IN183798B (da)
MY (2) MY120984A (da)
NO (2) NO995134L (da)
NZ (2) NZ337828A (da)
PE (2) PE84799A1 (da)
PL (2) PL195642B1 (da)
PT (1) PT875252E (da)
SI (1) SI0875252T1 (da)
SV (2) SV1998000051A (da)
TR (2) TR199902529T2 (da)
TW (2) TWI242443B (da)
UA (2) UA55448C2 (da)
WO (2) WO1998048822A1 (da)
ZA (2) ZA983497B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
PE84799A1 (es) 1997-04-28 1999-09-16 Lilly Co Eli Metodos mejorados para el procesamiento de proteina c activada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
ES2259248T3 (es) * 1998-11-13 2006-09-16 Eli Lilly And Company Uso de la proteina c humana para la preparacion de un medicamento para el tratamiento de trombocitopenia inducida por heparina.
AU2149800A (en) * 1998-11-20 2000-06-13 Eli Lilly And Company Method of treating viral hemorrhagic fever
CN1326357A (zh) * 1998-11-23 2001-12-12 伊莱利利公司 治疗镰刀形红细胞贫血病及地中海贫血病的方法
JP2002531519A (ja) * 1998-12-10 2002-09-24 イーライ・リリー・アンド・カンパニー 血栓性血小板減少性紫斑病および溶血性尿毒症性症候群の処置法
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
AU2002327649A1 (en) 2001-09-19 2003-04-01 Mcmaster University Treatment of sepsis with tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EP1446138A4 (en) 2001-10-15 2007-03-14 Novartis Vaccines & Diagnostic TREATMENT OF AN INFECTIOUS DISEASE BY THE ADMINISTRATION OF A LOW DOSE OF A TISSUE THROMBOPLASTINE ACCESS PATHWAY INHIBITOR (TFPI)
CN1607958A (zh) 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
NZ562480A (en) * 2002-10-29 2009-08-28 Alza Corp Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
KR20070007336A (ko) * 2004-03-17 2007-01-15 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 조직인자경로 억제제(tfpi)의 투여에 의한 중증지역사회획득 폐렴의 치료
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
US9175283B2 (en) * 2006-05-31 2015-11-03 Genzyme Corporation Use polysaccharides for promotion of enzymatic activity
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
TWI629064B (zh) * 2007-11-30 2018-07-11 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
BR112018074823B1 (pt) * 2016-06-01 2024-02-27 Servier IP UK Limited Composições liofilizadas, método de produção de uma composição, uso das composições e kit
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインcの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス,インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインc
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインc調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインcもしくは活性化プロテインcの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインcバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
PE84799A1 (es) 1997-04-28 1999-09-16 Lilly Co Eli Metodos mejorados para el procesamiento de proteina c activada
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EP0875563A3 (en) 2000-08-02
ZA983496B (en) 1999-10-25
JP2001527543A (ja) 2001-12-25
WO1998048818A1 (en) 1998-11-05
EA002149B1 (ru) 2001-12-24
EP0875563A2 (en) 1998-11-04
HUP0100284A2 (hu) 2001-06-28
IL132325A (en) 2005-07-25
ID22933A (id) 1999-12-16
BR9809304B1 (pt) 2011-02-08
AR012010A1 (es) 2000-09-13
CA2288143A1 (en) 1998-11-05
CA2288143C (en) 2012-08-21
US6436397B1 (en) 2002-08-20
CZ381099A3 (cs) 2000-03-15
DE69828330D1 (de) 2005-02-03
JP4383547B2 (ja) 2009-12-16
CO4940438A1 (es) 2000-07-24
EA199900980A1 (ru) 2000-04-24
CN1227025C (zh) 2005-11-16
NZ337828A (en) 2001-06-29
CN1254284A (zh) 2000-05-24
NO995134D0 (no) 1999-10-21
KR20010020325A (ko) 2001-03-15
UA73071C2 (en) 2005-06-15
ID23172A (id) 2000-03-23
EP0875252A3 (en) 2000-07-26
PE84799A1 (es) 1999-09-16
TR199902631T2 (xx) 2000-01-21
TW585871B (en) 2004-05-01
IN183798B (da) 2000-04-15
ATE285788T1 (de) 2005-01-15
PE86299A1 (es) 1999-09-17
EA199900979A1 (ru) 2000-06-26
JP2001524111A (ja) 2001-11-27
AR015598A1 (es) 2001-05-16
TWI242443B (en) 2005-11-01
CZ298429B6 (cs) 2007-10-03
HU224826B1 (en) 2006-02-28
SV1998000050A (es) 1999-01-13
PL336420A1 (en) 2000-06-19
BR9809292A (pt) 2000-07-04
PL195090B1 (pl) 2007-08-31
CA2287267A1 (en) 1998-11-05
MY120984A (en) 2005-12-30
KR100450856B1 (ko) 2004-10-02
ZA983497B (en) 1999-10-25
AU7258998A (en) 1998-11-24
US6159468A (en) 2000-12-12
PL336889A1 (en) 2000-07-17
IN187157B (da) 2002-02-16
PL195642B1 (pl) 2007-10-31
CN1261280A (zh) 2000-07-26
AU743531B2 (en) 2002-01-31
MY118591A (en) 2004-12-31
AU7161898A (en) 1998-11-24
WO1998048822A1 (en) 1998-11-05
HUP0003401A3 (en) 2003-01-28
ES2234072T3 (es) 2005-06-16
CA2287267C (en) 2006-08-15
KR100564189B1 (ko) 2006-03-27
PT875252E (pt) 2005-03-31
CN1235638C (zh) 2006-01-11
EA004881B1 (ru) 2004-08-26
EP0875252B1 (en) 2004-12-29
US6162629A (en) 2000-12-19
HUP0003401A2 (hu) 2001-02-28
EG23685A (en) 2007-05-09
HK1016472A1 (en) 1999-11-05
HUP0100284A3 (en) 2003-08-28
IL132325A0 (en) 2001-03-19
NO995134L (no) 1999-12-21
CO4950523A1 (es) 2000-09-01
DE69828330T2 (de) 2005-10-13
UA55448C2 (uk) 2003-04-15
IL132502A0 (en) 2001-03-19
EP0875252A2 (en) 1998-11-04
AU740753C (en) 2002-10-10
SI0875252T1 (en) 2005-06-30
TR199902529T2 (xx) 2000-02-21
US6395270B1 (en) 2002-05-28
NO995198L (no) 1999-10-25
JP4383546B2 (ja) 2009-12-16
SV1998000051A (es) 1998-12-11
AU740753B2 (en) 2001-11-15
NZ500346A (en) 2001-08-31
BR9809304A (pt) 2000-10-17
NO995198D0 (no) 1999-10-25
KR20010020242A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
DK0875252T3 (da) Formuleringer af aktiveret protein C
MA24473A1 (fr) Formulations
CY2006006I2 (el) Πρωτεϊνικα σκευασματα
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
DE69832185D1 (de) Dichroischer polarisator
ATA93198A (de) Fluoxetinpellets
NO20001494D0 (no) Overligger
ID23497A (id) Kombinasi pembungkus-deterjen
DE69801399D1 (de) Urladen
DE59803185D1 (de) Baulaser
DE69829006D1 (de) Triphendioxazinverbindungen
DK0862850T3 (da) Mejetærsker
ATA111897A (de) Kimme
ATE236897T1 (de) 3-benzylpiperidine
ATA112597A (de) Snowboard - bindung
ID23663A (id) Persiapan kaprolaktam
FR2766075B1 (fr) Combine fourchette-cuillere
FI974129A (fi) Apuväline
ATA46498A (de) Kunststoffgleitbahn
ITMI972543A0 (it) Proteina p27bbp
SE9704532D0 (sv) Kortställ
SE9700194D0 (sv) Hjälpmedel
NO970759D0 (no) Hjelpemiddel
LU90081B1 (fr) Serti plaque-clou
FI972858A0 (fi) Element foer en leksaksbyggsats